Operational Highlights of the 2025 Half Year Period and To Date
Expanding clinical development program evaluating the potential broad applicability of JNJ-1900 (NBTXR3) continues to build significant momentum:
First patient dosed in the CONVERGE study, a Johnson & Johnson ("J&J")-sponsored randomized Phase 2 study evaluating JNJ-1900 (NBTXR3) for patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab
First data announced from the completed dose escalation part of a Phase 1 study evaluating JNJ-1900 (NBTXR3) as a 2L+ therapy for patients with locally advanced NSCLC, sponsored by the University of Texas MD Anderson Cancer Center
Announced full data from the completed MD Anderson Phase 1 study evaluating JNJ-1900 (NBTXR3) in pancreatic cancer along with the launch of a new cohort and expansion of the trial
Achieved regulatory harmonization of JNJ-1900 (NBTXR3) after agreement with health authorities in major European countries to reclassify JNJ-1900 (NBTXR3) from a medical device to a drug
Filed a new composition of matter patent for JNJ-1900 (NBTXR3) that aims to reinforce the intellectual property foundation supporting the product candidate
First data announced from a Nanobiotix-sponsored Phase 1 study evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors for patients with primary cutaneous melanoma resistant to anti-PD-1
Updated data announced from a Nanobiotix-sponsored Phase 1 study continuing to support JNJ-1900 (NBTXR3) plus anti-PD-1 as a potential new 1L or 2L+ option in anti-PD-1 naïve or resistant R/M-HNSCC
Further execution of disciplined financial plan to reinforce pathway to long-term, self-sustained growth:
Strengthened financial position through amendment of the JNJ-1900 (NBTXR3) global licensing agreement extending cash visibility to mid-2026
In active discussions regarding non-dilutive financing, intended to meaningfully extend its cash runway beyond mid-2026.
Half Year 2025 Financial Results
Revenue and Other Income: Revenue and other income have increased for the six months ended June 30, 2025, up to €26.6 million, compared to €9.3 million for the same period in 2024. Further to J&J amendment letter signed in March 2025 reducing the Company's funding obligation on the future NANORAY-312 study costs, a positive non-cash revenue impact amounting to €21.2m was recorded in accordance with IFRS15 revenue recognition accounting principles application, offsetting the negative non-cash revenue impact recognized in 2024 results following the transfer of NANORAY-312 study sponsorship to J&J signed at the end of 2024. In addition, revenue towards J&J also included €3.4m of clinical product sales to J&J and R&D tax credit income of 1.7 million.
Research and Development ("R&D") Expenses: R&D expenses consist primarily of preclinical, clinical and manufacturing expenses including employee-related payroll expenses related to the development of JNJ-1900 (NBTXR3). These expenses for the six months ending June 30 2025, were €14.5 million compared to €22.0 million for the same period in 2024. This favorable ...
